Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to trea...
Gespeichert in:
| Veröffentlicht in: | Canadian Journal of Gastroenterology and Hepatology 2021, Vol.2021, p.5601678-9 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | |
| container_start_page | 5601678 |
| container_title | Canadian Journal of Gastroenterology and Hepatology |
| container_volume | 2021 |
| creator | Wei, Yulong Song, Qingzhu Zhang, Fenglan Yuan, Tian |
| description | Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to treat HCC required but also identification of the key genes involved in its pathogenesis is important for developing such therapies. This study found that olfactomedin 4 (OLFM4) level is higher in HCC patients than in healthy individuals. Furthermore, HCC patients also have higher messenger ribonucleic acid (mRNA) expression level in HCC tissues than in liver paracancerous tissues. OLFM4 has high predictive capacity as a biomarker for HCC and closely correlates to tumor size. It is confirmed that OLFM4 contributes to cancer cell proliferation, and HIF1α is involved in this process. Thus, the OLFM4/HIF-1α axis might be a target signaling pathway for developing novel drugs to treat HCC. |
| doi_str_mv | 10.1155/2021/5601678 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8668352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aba79d220f0447eea1b42ed23ce5ad63</doaj_id><sourcerecordid>2611360324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-a43c595c87a720e709a90df0aadb703e54475bf5884680da8b766403de00a163</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhlcIRKvSG2dkiSOEjr93L0g0akmkSuWQGwdrdj2bOGx2g70B-u_rNCGiF05jjR8_ntFbFG85fOJc6ysBgl9pA9zY8kVxLkTFJ8JW9uXpXFZnxWVKawDgQutKitfFmVQVF1bL8-L7fdduFJsnNgvLVffAbv5sI6VEnoWezaZT9g3HQP2YGPaeYS7sOgwbjD8oPrUWK4q4pd0YGrbAuKSRtUPcP31TvGqxS3R5rBfF4vZmMZ1N7u6_zqdf7iaNsnycoJKNrnRTWrQCyEKFFfgWEH1tQZJWyuq61WWpTAkey9oao0B6AkBu5EUxP2j9gGu3jSEP9-AGDO6pMcSlw5in68hhjbbyQkALWUqEvFaCvJANafRGZtfng2u7qzfkm7x4xO6Z9PlNH1ZuOfxypTGl1CIL3h8Fcfi5ozS69bCLfV7fCcO5NCCFytTHA9XEIaVI7ekHDm4frNsH647BZvzdv1Od4L8xZuDDAViF3uPv8H_dI3-yqI0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2611360324</pqid></control><display><type>article</type><title>Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Wei, Yulong ; Song, Qingzhu ; Zhang, Fenglan ; Yuan, Tian</creator><contributor>Granito, Alessandro ; Alessandro Granito</contributor><creatorcontrib>Wei, Yulong ; Song, Qingzhu ; Zhang, Fenglan ; Yuan, Tian ; Granito, Alessandro ; Alessandro Granito</creatorcontrib><description>Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to treat HCC required but also identification of the key genes involved in its pathogenesis is important for developing such therapies. This study found that olfactomedin 4 (OLFM4) level is higher in HCC patients than in healthy individuals. Furthermore, HCC patients also have higher messenger ribonucleic acid (mRNA) expression level in HCC tissues than in liver paracancerous tissues. OLFM4 has high predictive capacity as a biomarker for HCC and closely correlates to tumor size. It is confirmed that OLFM4 contributes to cancer cell proliferation, and HIF1α is involved in this process. Thus, the OLFM4/HIF-1α axis might be a target signaling pathway for developing novel drugs to treat HCC.</description><identifier>ISSN: 2291-2789</identifier><identifier>EISSN: 2291-2797</identifier><identifier>DOI: 10.1155/2021/5601678</identifier><identifier>PMID: 34912753</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Biomarkers ; Biopsy ; Breast cancer ; Cancer therapies ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Cell Proliferation ; Chemotherapy ; Granulocyte Colony-Stimulating Factor ; Hepatitis B ; Hepatitis C ; Humans ; Hypoxia ; Kinases ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Lung cancer ; Medical prognosis ; Pathogenesis ; Patients ; Proteins ; Survival analysis ; Tumors</subject><ispartof>Canadian Journal of Gastroenterology and Hepatology, 2021, Vol.2021, p.5601678-9</ispartof><rights>Copyright © 2021 Yulong Wei et al.</rights><rights>Copyright © 2021 Yulong Wei et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Yulong Wei et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c471t-a43c595c87a720e709a90df0aadb703e54475bf5884680da8b766403de00a163</cites><orcidid>0000-0003-2055-7300</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668352/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668352/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,873,881,4010,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34912753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Granito, Alessandro</contributor><contributor>Alessandro Granito</contributor><creatorcontrib>Wei, Yulong</creatorcontrib><creatorcontrib>Song, Qingzhu</creatorcontrib><creatorcontrib>Zhang, Fenglan</creatorcontrib><creatorcontrib>Yuan, Tian</creatorcontrib><title>Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC</title><title>Canadian Journal of Gastroenterology and Hepatology</title><addtitle>Can J Gastroenterol Hepatol</addtitle><description>Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to treat HCC required but also identification of the key genes involved in its pathogenesis is important for developing such therapies. This study found that olfactomedin 4 (OLFM4) level is higher in HCC patients than in healthy individuals. Furthermore, HCC patients also have higher messenger ribonucleic acid (mRNA) expression level in HCC tissues than in liver paracancerous tissues. OLFM4 has high predictive capacity as a biomarker for HCC and closely correlates to tumor size. It is confirmed that OLFM4 contributes to cancer cell proliferation, and HIF1α is involved in this process. Thus, the OLFM4/HIF-1α axis might be a target signaling pathway for developing novel drugs to treat HCC.</description><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Cell Proliferation</subject><subject>Chemotherapy</subject><subject>Granulocyte Colony-Stimulating Factor</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Kinases</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Proteins</subject><subject>Survival analysis</subject><subject>Tumors</subject><issn>2291-2789</issn><issn>2291-2797</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU1vEzEQhlcIRKvSG2dkiSOEjr93L0g0akmkSuWQGwdrdj2bOGx2g70B-u_rNCGiF05jjR8_ntFbFG85fOJc6ysBgl9pA9zY8kVxLkTFJ8JW9uXpXFZnxWVKawDgQutKitfFmVQVF1bL8-L7fdduFJsnNgvLVffAbv5sI6VEnoWezaZT9g3HQP2YGPaeYS7sOgwbjD8oPrUWK4q4pd0YGrbAuKSRtUPcP31TvGqxS3R5rBfF4vZmMZ1N7u6_zqdf7iaNsnycoJKNrnRTWrQCyEKFFfgWEH1tQZJWyuq61WWpTAkey9oao0B6AkBu5EUxP2j9gGu3jSEP9-AGDO6pMcSlw5in68hhjbbyQkALWUqEvFaCvJANafRGZtfng2u7qzfkm7x4xO6Z9PlNH1ZuOfxypTGl1CIL3h8Fcfi5ozS69bCLfV7fCcO5NCCFytTHA9XEIaVI7ekHDm4frNsH647BZvzdv1Od4L8xZuDDAViF3uPv8H_dI3-yqI0</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Wei, Yulong</creator><creator>Song, Qingzhu</creator><creator>Zhang, Fenglan</creator><creator>Yuan, Tian</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2055-7300</orcidid></search><sort><creationdate>2021</creationdate><title>Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC</title><author>Wei, Yulong ; Song, Qingzhu ; Zhang, Fenglan ; Yuan, Tian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-a43c595c87a720e709a90df0aadb703e54475bf5884680da8b766403de00a163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Cell Proliferation</topic><topic>Chemotherapy</topic><topic>Granulocyte Colony-Stimulating Factor</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Kinases</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Proteins</topic><topic>Survival analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, Yulong</creatorcontrib><creatorcontrib>Song, Qingzhu</creatorcontrib><creatorcontrib>Zhang, Fenglan</creatorcontrib><creatorcontrib>Yuan, Tian</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Canadian Journal of Gastroenterology and Hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, Yulong</au><au>Song, Qingzhu</au><au>Zhang, Fenglan</au><au>Yuan, Tian</au><au>Granito, Alessandro</au><au>Alessandro Granito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC</atitle><jtitle>Canadian Journal of Gastroenterology and Hepatology</jtitle><addtitle>Can J Gastroenterol Hepatol</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>5601678</spage><epage>9</epage><pages>5601678-9</pages><issn>2291-2789</issn><eissn>2291-2797</eissn><abstract>Hepatocellular carcinoma (HCC) is one of the primary types of cancer that claims many lives worldwide, and its incidence continues to increase. Conventional therapies against liver cancer are inadequate, and the pathogenesis of HCC remains unclear. Thus, not only are more effective therapies to treat HCC required but also identification of the key genes involved in its pathogenesis is important for developing such therapies. This study found that olfactomedin 4 (OLFM4) level is higher in HCC patients than in healthy individuals. Furthermore, HCC patients also have higher messenger ribonucleic acid (mRNA) expression level in HCC tissues than in liver paracancerous tissues. OLFM4 has high predictive capacity as a biomarker for HCC and closely correlates to tumor size. It is confirmed that OLFM4 contributes to cancer cell proliferation, and HIF1α is involved in this process. Thus, the OLFM4/HIF-1α axis might be a target signaling pathway for developing novel drugs to treat HCC.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>34912753</pmid><doi>10.1155/2021/5601678</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2055-7300</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2291-2789 |
| ispartof | Canadian Journal of Gastroenterology and Hepatology, 2021, Vol.2021, p.5601678-9 |
| issn | 2291-2789 2291-2797 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8668352 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Biomarkers Biopsy Breast cancer Cancer therapies Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Cell Proliferation Chemotherapy Granulocyte Colony-Stimulating Factor Hepatitis B Hepatitis C Humans Hypoxia Kinases Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - genetics Lung cancer Medical prognosis Pathogenesis Patients Proteins Survival analysis Tumors |
| title | Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A58%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Olfm4%20Is%20Highly%20Expressed%20in%20HCC%20Patients%20and%20as%20a%20Biomarker%20and%20Therapeutic%20Target%20for%20HCC&rft.jtitle=Canadian%20Journal%20of%20Gastroenterology%20and%20Hepatology&rft.au=Wei,%20Yulong&rft.date=2021&rft.volume=2021&rft.spage=5601678&rft.epage=9&rft.pages=5601678-9&rft.issn=2291-2789&rft.eissn=2291-2797&rft_id=info:doi/10.1155/2021/5601678&rft_dat=%3Cproquest_doaj_%3E2611360324%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2611360324&rft_id=info:pmid/34912753&rft_doaj_id=oai_doaj_org_article_aba79d220f0447eea1b42ed23ce5ad63&rfr_iscdi=true |